The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice
Venue: Hyatt Regency Boston, One Avenue de Lafayette, Boston, MA, United States
Official conference page for The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice . https://binaytara.org/projects/conferences/the-international-gynecologic-oncology-consensus-conference-marrying-evidence-to-practice-1
About The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice
Conference program and agenda
Our Agenda
Day 1: Friday, November 6th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Anuja Jhingran
01:20 PM - 01:40 PM
Molecular staging of endometrial cancer: approach to p53 abnormal tumors – Carol Aghajanian
01:40 PM - 02:00 PM
A critical review of the role of radiation in early-stage endometrial cancer – Ann Klopp
02:00 PM - 02:15 PM
Discussion
02:15 PM - 02:30 PM
Vote (audience participation, panel vote)
Session Chair: Stephanie Lherueux
02:45 PM - 03:05 PM
Adjuvant PARP inhibitors: Update on long-term benefit
03:05 PM - 03:25 PM
Is there a role for PARPi after progression on a prior PARPi?
03:25 PM - 03:40 PM
Discussion
03:40 PM - 03:55 PM
Vote (audience participation, panel vote)
Session Chair: Linda Duska
04:05 PM - 04:25 PM
The current state of FOLR1 directed treatments: mirvetuximab and beyond
04:25 PM - 04:45 PM
B96 Trial – Domenica Lorusso
04:45 PM - 05:00 PM
Rosella
05:00 PM - 05:15 PM
Discussion
05:15 PM - 05:30 PM
Vote (audience participation, panel vote)
Day 2: Saturday, November 7th, 2026
Session Chair: Dmitriy Zamarin
08:10 AM - 08:30 AM
The role of ADCs in endometrial cancer
08:30 AM - 08:50 AM
Targeting HER2: is earlier better?
08:50 AM - 09:10 AM
Discussion
09:10 AM - 09:25 AM
Vote (audience participation, panel vote)
Session Chair: Katina Robison
09:40 AM - 10:00 AM
The role of checkpoint inhibitors in dMMR endometrial cancer – Ramez Eskander
10:00 AM - 10:20 AM
Options and endpoints with adjuvant RT for endometrial cancer
10:20 AM - 10:40 AM
POLE-endometrial cancer: Does stage matter?
10:40 AM - 11:00 AM
A critical evaluation of checkpoint inhibitors in cervical cancer: PD-L1 and beyond
11:00 AM - 11:30 AM
Discussion
11:30 AM - 11:45 AM
Vote (audience participation, panel vote)
01:00 PM - 01:20 PM
A look at primary treatment of cervical cancer: Making sense of A18 and Interlace
01:20 PM - 01:40 PM
The role of surgery in metastatic endometrial cancer
01:40 PM - 02:00 PM
MRD monitoring in ovarian cancer: Time has come or not just yet?
02:00 PM - 02:30 PM
Discussion
02:30 PM - 02:45 PM
Vote (audience participation, panel vote)